{"id":1018,"date":"2024-11-06T16:47:42","date_gmt":"2024-11-06T16:47:42","guid":{"rendered":"https:\/\/injurycenter.umich.edu\/michigan-safer-opioid-prescribing-toolkit\/?page_id=1018"},"modified":"2026-05-12T14:07:36","modified_gmt":"2026-05-12T18:07:36","slug":"moud","status":"publish","type":"page","link":"https:\/\/injurycenter.umich.edu\/safer-prescribing-toolkit\/moud\/","title":{"rendered":"MOUD"},"content":{"rendered":"
\n\n

Medication For Opioid Use Disorder (MOUD)<\/h1>\n\n\n\n

 While many valuable resources in the Safer Prescribing Toolkit still use the term \u201cMAT,\u201d our website will refer to it as \u201cMOUD\u201d as this term generally carries less stigma.<\/strong><\/em><\/p>\n\n\n\n

The goal of MOUD is to reduce or eliminate harmful opioid cravings and illicit use, encourage treatment engagement, and improve the patient\u2019s quality of life. Any clinician with a DEA license can prescribe buprenorphine for OUD since the elimination of the federal waiver requirement in 2022. There is no \u201cone-size-fits-all\u201d approach for MOUD initiation, and the basic steps listed below should be tailored to individual needs. Please look at the resources listed below for comprehensive information.<\/p>\n\n<\/div>\n\n

\n\n

Buprenorphine and methadone are first-line medications<\/h2>\n\n\n\n

There are three evidence-based medications to treat opioid use disorder:<\/p>\n\n\n

\n
\n\n

Buprenorphine<\/strong> is a partial opioid agonist and the most practical option for primary care clinicians. Buprenorphine is available in various formulations with and without naloxone.<\/p>\n\n\n

\n\n

The FDA-approved formulations include:<\/strong><\/p>\n\n\n\n